Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00488592|
Recruitment Status : Completed
First Posted : June 20, 2007
Results First Posted : July 9, 2014
Last Update Posted : July 9, 2014
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Myelodysplastic Syndrome (MDS)
Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Biological: PR1:169-177 Peptide
Drug: GM-CSF (Sargramostim)
Biological: Montanide adjuvant
Although not tested or described formally, no clinically meaningful hematological responses were seen.
Despite boosting, cellular immune responses were only transient.